T cell redirection as a new standard of care for relapsed multiple myeloma: impact on inpatient capacity, financial burden and infrastructural requirements in Germany.
作者信息
Ahmadi P, Alsdorf W, Leypoldt L, Kosch R, Schaefers C, Gagelmann N, Ayuk F, Kron F, Weisel K
机构信息
Controlling University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
出版信息
Bone Marrow Transplant. 2025 Apr;60(4):538-540. doi: 10.1038/s41409-024-02505-x. Epub 2025 Jan 22.
Abstract
摘要
相似文献
1
T cell redirection as a new standard of care for relapsed multiple myeloma: impact on inpatient capacity, financial burden and infrastructural requirements in Germany.
Bone Marrow Transplant. 2025 Apr;60(4):538-540. doi: 10.1038/s41409-024-02505-x. Epub 2025 Jan 22.
2
Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy.
Blood Adv. 2024 Jun 25;8(12):3038-3044. doi: 10.1182/bloodadvances.2024012724.
3
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma.
Blood Adv. 2023 Mar 28;7(6):1056-1064. doi: 10.1182/bloodadvances.2022007923.
4
Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed/refractory multiple myeloma.
Front Oncol. 2024 Aug 8;14:1455464. doi: 10.3389/fonc.2024.1455464. eCollection 2024.
5
Patient Perceptions Regarding Multiple Myeloma and Its Treatment: Qualitative Evidence from Interviews with Patients in the United Kingdom, France, and Germany.
Patient. 2021 Sep;14(5):613-623. doi: 10.1007/s40271-021-00501-7. Epub 2021 Mar 9.
6
Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Transplant Cell Ther. 2024 Jan;30(1):17-37. doi: 10.1016/j.jtct.2023.10.022. Epub 2023 Oct 31.
7
T-cell redirection therapy after allogeneic stem cell transplantation in multiple myeloma: When the cure fails!
Br J Haematol. 2024 Mar;204(3):753-754. doi: 10.1111/bjh.19267. Epub 2023 Dec 18.
8
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study.
Blood. 2024 Aug 8;144(6):615-628. doi: 10.1182/blood.2023022823.
9
Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab.
Clin Lymphoma Myeloma Leuk. 2024 Oct;24(10):665-693.e14. doi: 10.1016/j.clml.2024.05.003. Epub 2024 May 15.
10
Immunotherapy in multiple myeloma: when, where, and for who?
Curr Opin Oncol. 2020 Nov;32(6):664-671. doi: 10.1097/CCO.0000000000000677.
引用本文的文献
1
Bioinformatics analysis of intrinsic drivers of immune dysregulation in multiple myeloma to elucidate immune phenotypes and discover prognostic gene signatures.
Sci Rep. 2025 May 5;15(1):15662. doi: 10.1038/s41598-025-00074-7.
本文引用的文献
1
Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma.
Future Oncol. 2024;20(18):1221-1235. doi: 10.2217/fon-2023-0954. Epub 2024 Apr 23.
2
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy.
Blood. 2024 Apr 18;143(16):1565-1575. doi: 10.1182/blood.2023022432.
3
The Impact of Outpatient versus Inpatient Administration of CAR-T Therapies on Clinical, Economic, and Humanistic Outcomes in Patients with Hematological Cancer: A Systematic Literature Review.
Cancers (Basel). 2023 Dec 7;15(24):5746. doi: 10.3390/cancers15245746.
4
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
N Engl J Med. 2023 Mar 16;388(11):1002-1014. doi: 10.1056/NEJMoa2213614. Epub 2023 Feb 10.
5
Treatment horizon in multiple myeloma.
Eur J Haematol. 2022 Nov;109(5):425-440. doi: 10.1111/ejh.13840. Epub 2022 Sep 18.
6
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma.
Leukemia. 2022 May;36(5):1371-1376. doi: 10.1038/s41375-022-01531-2. Epub 2022 Mar 24.
7
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
N Engl J Med. 2021 Feb 25;384(8):705-716. doi: 10.1056/NEJMoa2024850.
8
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Leukemia. 2019 Sep;33(9):2266-2275. doi: 10.1038/s41375-019-0435-7. Epub 2019 Mar 11.
Zotero 插件